Roles for Growth factors in Tumor Progression: Opportunities for Cancer Therapy
Pr Yosef YARDEN
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
Friday, December 7th 2018 - 11 a.m.
- Auditorium, IGBMC
Hosted by Fabien ALPY & Catherine-Laure TOMASETTO
While the majority of tumors are initiated by genetic aberrations, all malignant lesions follow a subsequent step-wise progression phase, which involves growth factors and their cognate receptors. Unlike many oncogenic mutations, growth factors and their receptor tyrosine kinases are amenable to pharmacological interception. My lecture will focus on the group of EGF-like growth factors and their ERBB/HER family receptors. I will highlight the principles of signal transduction networks and focus on the complex transcriptional programs that underlay EGF-to-ERBB signaling. The second part of my lecture will exemplify the opportunities offered by pharmacological targeting of growth factor signaling, including clinically approved drugs, experimental strategies and ways to overcome resistance to molecular targeted therapies.